Guest Columns & From The Editor

  1. How AbbVie's Digital Transformation Brought Platform Knowledge Closer 9/9/2025

    A custom-built digital ecosystem reduced the time spent on documentation in AbbVie's bioprocess development labs by about 70% for some experiment types.

  2. Optimizing Lentiviral Vectors For Allogeneic CAR-T Manufacturing 9/5/2025

    A group of graduate researchers explored VSV-G affinity chromatography as an alternative to the standard anion exchange chromatography or AEX.

  3. Contract Manufacturing Outsourcing Trends For Advanced Therapies In 2025 And Beyond 9/4/2025

    Contract manufacturing continues to emerge as the widely adopted model for bringing cell therapies, gene therapies, RNA therapeutics, and oligonucleotides to patients worldwide.

  4. Building The Biopharma Manufacturing Facility Of The Future Requires A Phased IT/OT Strategy 9/4/2025

    Your pharma or biotech company can take these actionable steps to achieve digital facility operations and successfully build your own facility of the future. 

  5. New Group Wants 'Phase-Appropriate' Thinking To Retire 9/4/2025

    Decisions in cell and gene therapy are not about aligning with arbitrary clinical phases but about balancing risk.

  6. Using Slot Management To Bridge The Gap Between Capacity And CGTs 9/3/2025

    Optimizing slot management is essential for cell and gene therapy manufacturers to overcome high costs, long turnaround times, and limited patient access by enabling real-time scheduling, better resource utilization, and advanced technology integration.

  7. Lilly's Exploring A Universal AAV Purification Method 9/2/2025

    Serotype-specific resins don't scale gracefully. One team at Eli Lilly and Company is exploring an alternative that skips affinity resins altogether.

     

  8. FDA Report Details FY24 Inspections, Shows Big Uptick In Key Countries 8/29/2025

    The 2024 Report on the State of Pharmaceutical Quality shows the agency's efforts to normalize post-pandemic oversight under the previous administration.

  9. Precigen Secures FDA Approval For PAPZIMEOS And Redefines RRP Treatment 8/27/2025

    Precigen has received FDA approval for PAPZIMEOS, the first therapy for recurrent respiratory papillomatosis, marking a major advance in patient care.

  10. Navigating Regulatory Complexity In Cell And Gene Therapy 8/26/2025

    This is a recap of the first three episodes of FDA Fridays, a special four-week series from Cell & Gene: The Podcast. These conversations shed light on the current challenges, best practices, and forward-looking strategies shaping the CGT regulatory environment.